alexa Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy.
Pharmaceutical Sciences

Pharmaceutical Sciences

Advances in Pharmacoepidemiology and Drug Safety

Author(s): Lu DY, Chen XL, Ding J

Abstract Share this page

Abstract The accumulation of fibrin/fibrinogen and other coagulation factors in and around solid tumors and metastatic foci has been recognized for a century as an aspect of cancer pathology. On this basis, anticoagulants and fibrinolytic agents have been deployed as adjuvant anticancer therapies, but they have proved clinically useful for only a small proportion of tumors and they only control the functions of the coagulant components. Overuse or long-term application of anticoagulants and fibrinolytic agents often lead to undesirable side-effects. Here, we propose that anticancer drugs that act by different mechanisms can inhibit tumor-associated coagulation, and it may be possible to develop drugs that specifically targeting tumor-related coagulation, have specific cytotoxic effects on tumor and metastatic cells. We provide laboratory and clinical evidence supporting the hypothesis and offer proposals for future applications. This article was published in Med Hypotheses and referenced in Advances in Pharmacoepidemiology and Drug Safety

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version